Insider Transactions in Q4 2018 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q4 2018)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 27
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,461
+0.51%
|
$659,064
$24.95 P/Share
|
|
Dec 26
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
12,737
+0.24%
|
$305,688
$24.89 P/Share
|
|
Dec 24
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
68,000
+0.42%
|
$1,564,000
$23.69 P/Share
|
|
Dec 21
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
22,742
+0.43%
|
$500,324
$22.58 P/Share
|
|
Dec 18
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
69,925
-5.67%
|
$2,027,825
$29.7 P/Share
|
|
Dec 17
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
3,009
-0.24%
|
$99,297
$33.17 P/Share
|
|
Dec 07
2018
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,500
+11.39%
|
$21,500
$1.81 P/Share
|
|
Dec 01
2018
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-0.51%
|
$28,158
$38.33 P/Share
|
|
Nov 21
2018
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
80,000
-1.88%
|
$1,520,000
$19.25 P/Share
|